Sodium-Glucose Cotransporter-2 (SGLT-2) Attenuates Serum Uric Acid (SUA) Level in Patients with Type 2 Diabetes

Table 1

Baseline demographics characteristics ().

Baseline parameters	Group A^a	Group B^b	value
Age in years ()			0.629
Male, (%)	24 (68.5%)	20 (57%)	0.170
Female, (%)	11 (31.1%)	15 (42.8%)	0.23
Duration of diabetes in years ()			0.236
Body weight in kg ()			0.324
BMI in kg/m^2 ()			0.763
Blood pressure systolic in mmHg ()			0.671
Blood pressure diastolic mmHg ()			0.162
Fasting blood glucose in mg/dl ()			0.68
HbA1c ()			0.682
Serum uric acid level in mg/dl ()			0.36

^aSGLT-2 inhibitors (): empagliflozin () and dapagliflozin (). ^bStandard OAD therapy (). -test between two groups. Abbreviations: BMI: body mass index; HbA1c: glycated hemoglobin; OAD: oral antihyperglycemic drug; SD: standard deviation; SGLT-2: sodium-glucose cotransporter-2.